Analysts expect OraSure Technologies, Inc. (NASDAQ:OSUR) to announce sales of $47.04 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for OraSure Technologies’ earnings. The lowest sales estimate is $46.97 million and the highest is $47.10 million. OraSure Technologies reported sales of $50.25 million during the same quarter last year, which indicates a negative year over year growth rate of 6.4%. The company is scheduled to report its next earnings report on Wednesday, February 5th.
According to Zacks, analysts expect that OraSure Technologies will report full-year sales of $151.95 million for the current fiscal year, with estimates ranging from $151.90 million to $152.00 million. For the next fiscal year, analysts anticipate that the business will post sales of $170.81 million, with estimates ranging from $164.00 million to $177.61 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow OraSure Technologies.
OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Wednesday, November 6th. The medical instruments supplier reported $0.21 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.18. OraSure Technologies had a return on equity of 5.93% and a net margin of 15.80%. The business had revenue of $35.99 million for the quarter, compared to the consensus estimate of $38.62 million. During the same quarter last year, the business posted $0.13 earnings per share. The company’s revenue for the quarter was down 21.6% on a year-over-year basis.
Several research analysts have recently commented on OSUR shares. BidaskClub upgraded OraSure Technologies from a “sell” rating to a “hold” rating in a report on Saturday, November 30th. Zacks Investment Research downgraded OraSure Technologies from a “hold” rating to a “sell” rating in a report on Tuesday, December 3rd. Canaccord Genuity reiterated a “hold” rating and issued a $8.00 price objective on shares of OraSure Technologies in a report on Monday, November 11th. Finally, ValuEngine upgraded OraSure Technologies from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd.
NASDAQ OSUR traded up $0.23 during trading hours on Tuesday, reaching $7.97. 475,949 shares of the stock traded hands, compared to its average volume of 483,069. The stock has a 50 day simple moving average of $8.23 and a two-hundred day simple moving average of $8.06. OraSure Technologies has a 1 year low of $6.35 and a 1 year high of $13.25. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.72 and a quick ratio of 6.85. The company has a market cap of $477.76 million, a price-to-earnings ratio of 28.67, a price-to-earnings-growth ratio of 4.42 and a beta of 1.19.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. increased its holdings in shares of OraSure Technologies by 3.0% in the second quarter. BlackRock Inc. now owns 9,391,915 shares of the medical instruments supplier’s stock worth $87,157,000 after buying an additional 273,670 shares during the period. Renaissance Technologies LLC increased its holdings in shares of OraSure Technologies by 14.0% in the second quarter. Renaissance Technologies LLC now owns 4,965,803 shares of the medical instruments supplier’s stock worth $46,083,000 after buying an additional 610,300 shares during the period. D. E. Shaw & Co. Inc. increased its holdings in shares of OraSure Technologies by 67.1% in the second quarter. D. E. Shaw & Co. Inc. now owns 2,971,866 shares of the medical instruments supplier’s stock worth $27,579,000 after buying an additional 1,193,709 shares during the period. Systematic Financial Management LP increased its holdings in shares of OraSure Technologies by 10.7% in the third quarter. Systematic Financial Management LP now owns 1,495,248 shares of the medical instruments supplier’s stock worth $11,170,000 after buying an additional 144,412 shares during the period. Finally, Nuveen Asset Management LLC purchased a new position in shares of OraSure Technologies in the second quarter worth about $12,979,000. Hedge funds and other institutional investors own 95.66% of the company’s stock.
About OraSure Technologies
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Featured Article: Penny Stocks, Risk and Reward Factors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.